Alzamend Neuro (ALZN) EBITDA (2020 - 2026)

Alzamend Neuro has disclosed EBITDA across 7 years of filings, most recently posting -$2.9 million for Q2 2026.

• In Q2 2026, EBITDA fell 152.07% year-over-year to -$2.9 million; the TTM figure through Apr 2026 stood at -$8.8 million (down 94.96% YoY), while the FY2026 annual figure was -$8.8 million, down 94.96% from the prior year.
• EBITDA came in at -$2.9 million for Q2 2026 at Alzamend Neuro, down from -$2.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$850064.0 in Q2 2024 to a low of -$5.4 million in Q1 2023.
• Average EBITDA over 5 years is -$2.5 million, with a median of -$2.7 million recorded in 2024.
• Year-over-year, EBITDA slumped 217.45% in 2022 and jumped 74.28% in 2024.
• Over 5 years, EBITDA stood at -$3.1 million in 2022, then increased by 6.59% to -$2.9 million in 2023, then surged by 53.2% to -$1.4 million in 2024, then climbed by 26.51% to -$998109.0 in 2025, then slumped by 187.63% to -$2.9 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$2.9 million in Q2 2026, -$2.2 million in Q1 2026, and -$998109.0 in Q4 2025.